HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nomura, N. Articles by Mishima, A. Search for Related Content PubMed PubMed Citation Articles by Nomura, N. Articles by Mishima, A. Related Collections Lung - other

Ann Thorac Surg 2003;76:237-243
© 2003 The Society of Thoracic Surgeons

---

Original article: general thoracic

Cardiotrophin-1 is a prophylactic against the development of chronic hypoxic pulmonary hypertension in rats

^a Department of Cardiovascular Surgery, Nagoya, Japan
^b Department of Regulatory Cell Physiology, Nagoya, Japan
^c Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Accepted for publication February 12, 2003.

^* Address reprint requests to Dr Mishima, Department of Cardiovascular Surgery, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
e-mail: mishima{at}med.nagoya-cu.ac.jp

BACKGROUND: Cardiotrophin-1 (CT-1) reduces arterial blood pressure by activating nitric oxide synthesis. This study attempted to elucidate the effect of CT-1 on pulmonary arteries of pulmonary hypertensive rats.

METHODS: Pulmonary hypertension was induced in rats in a hypoxic chamber containing 10% to 11% oxygen. Rats kept in the hypoxic environment received either recombinant mouse CT-1 at a concentration of 50 µg/kg (CT-1+hypoxia group, n = 21) or phosphate-buffered saline (hypoxia group, n = 30) once per day. Control rats housed in room air also received either the equivalent concentration of CT-1 (CT-1+normoxia group, n = 18) or phosphate-buffered saline (normoxia group, n = 39). Pulmonary arterial pressure, pulmonary vasorelaxation, and ventricular hypertrophy were measured.

RESULTS: The mean pulmonary arterial pressures were as follows (from lowest to highest; p values are relative to the hypoxia group): normoxia group (20.3 ± 4.0 mm Hg, p < 0.0001), CT-1+normoxia group (21.1 ± 2.4 mm Hg, p < 0.0001), CT-1+hypoxia group (27.9 ± 4.1 mm Hg, p = 0.0019), and hypoxia group (33.9 ± 6.6 mm Hg). The endothelium-dependent vasorelaxation value was largest in the normoxia group (59.5% ± 17.4%, p < 0.0001), with it decreasing in the other groups in the following order (p values are relative to the hypoxia group): CT-1+normoxia group (52.8% ± 15.5%, p = 0.0005), CT-1+hypoxia group (42.3% ± 14.8%, p = 0.0061), and hypoxia group (17.4% ± 4.8%). Right ventricular hypertrophy was significant only in the hypoxia group.

CONCLUSIONS: Our results demonstrate that treatment with CT-1 in a chronic hypoxic pulmonary hypertension model protects the endothelial function of the pulmonary artery; decreases pulmonary arterial pressure; and attenuates right ventricular hypertrophy.

This article has been cited by other articles:

				D. W. Ho, Z. F. Yang, C. K. Lau, K. H. Tam, J. Y. To, R. T. Poon, and S. T. Fan Therapeutic Potential of Cardiotrophin 1 in Fulminant Hepatic Failure: Dual Roles in Antiapoptosis and Cell Repair Arch Surg, November 1, 2006; 141(11): 1077 - 1084. [Abstract] [Full Text] [PDF]

				C. J. Pemberton, S. D. Raudsepp, T. G. Yandle, V. A. Cameron, and A. M. Richards Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch Cardiovasc Res, October 1, 2005; 68(1): 109 - 117. [Abstract] [Full Text] [PDF]